QuantaFlo® Enables Large-Scale Home-Based PAD Detection: Clinical Study Reveals Feasibility for Older Medicare Patients

Semler Scientific, Inc. (Nasdaq: SMLR) has made a significant advancement in preventive cardiovascular screening. Recent data published in AJPM Focus—the official open-access journal of The American College of Preventive Medicine and the Association for Prevention Teaching and Research—showcases how QuantaFlo®, the company’s innovative PAD diagnostic technology, can be effectively deployed for in-home screening across diverse patient populations.

Key Study Findings: What the Data Reveals

The research examined screening results from nearly 200,000 Medicare Advantage beneficiaries aged 65 and older who participated in the Optum HouseCalls program. Among these 192,500 patients who received home-based PAD screening using QuantaFlo®, over one-quarter—specifically 27.7%—tested positive for peripheral artery disease. This substantial prevalence rate underscores how common undiagnosed PAD remains among seniors.

More importantly, patients whose QuantaFlo® screening identified PAD showed dramatically worse clinical outcomes compared to those who screened negative. Within one year, PAD-positive patients experienced significantly elevated rates of all-cause mortality, major adverse cardiovascular events (MACE), and major adverse limb events (MALE)—all differences were statistically significant.

Why In-Home Screening with QuantaFlo® Matters

The traditional approach to PAD diagnosis often misses cases because many older adults don’t seek screening or visit clinics regularly. This study, conducted between April 2017 and February 2019 using real-world conditions, demonstrates that bringing QuantaFlo® technology directly to patients’ homes overcomes significant barriers to detection.

By identifying PAD early in a home setting, healthcare providers can intervene sooner, potentially preventing serious complications. The data suggests that widespread adoption of convenient, at-home QuantaFlo® screening could translate into better health outcomes for Medicare Advantage populations—a group especially vulnerable to cardiovascular complications.

Clinical Implications for Preventive Care

The research published in AJPM Focus provides evidence that feasibility isn’t the only benefit; the detection rates and outcome data demonstrate clinical utility. For Medicare Advantage plans and healthcare networks seeking to reduce adverse events while improving preventive care quality, QuantaFlo® represents a scalable solution that meets patients where they are rather than requiring them to travel to medical facilities.